Comparison of High- Versus Low-Dose Aspirin for Pregnancy Outcomes in Women at High Risk of Preeclampsia

ConditionPreeclampsia
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-45
SponsorMedicare Hospital (Pvt) Limited

About this trial

The goal of this randomized clinical trial is to compare the effects of two doses of aspirin, 75 mg and 150 mg, in pregnant women who are at high risk of developing preeclampsia.

The main question the study aims to answer is:

1. Does taking 150 mg of aspirin reduce the occurrence of preeclampsia more effectively than taking 75 mg of aspirin in pregnant women at high risk of preeclampsia? 2. Are there differences in stillbirth and newborn birth weight between the two aspirin doses?

The study will include 224 pregnant women aged 18-45 years who are between 11 and 14 weeks of pregnancy and are identified as being at high risk for preeclampsia. Participants will be randomly assigned to one of two groups.

* Participants in the low-dose group will take 75 mg of aspirin once daily at bedtime. * Participants in the high-dose group will take 150 mg of aspirin once daily at bedtime.

Participants will continue their assigned aspirin dose until 36 weeks of pregnancy and will be followed every 2 weeks until delivery.

The study will record whether participants develop preeclampsia and whether stillbirth occurs. The birth weight of each newborn will also be measured within 3 hours of birth.

The study hypothesis is that 150 mg of aspirin will result in a lower incidence of preeclampsia than 75 mg of aspirin in pregnant women at high risk of preeclampsia.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Gestational age 11-14 weeks

High risk of preeclampsia

Disqualifiers

Active gastritis

Abnormal coagulation profile (INR > 1.5)

Renal disease

Platelet count < 150,000/mm^3

Trial design

Design model

Parallel

Treatments tested in this trial

  • Aspirin

    Drug

    Aspirin 75 mg administered orally once daily at bedtime from 11-14 weeks of pregnancy until 36 weeks of pregnancy.

  • Aspirin

    Drug

    Aspirin 150 mg administered orally once daily at bedtime from 11-14 weeks of pregnancy until 36 weeks of pregnancy

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Low-dose AspirinActive comparator 1 intervention
Group B: High-dose AspirinExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Incidence of Preeclampsia

Proportion of participants who develop preeclampsia after 20 weeks of pregnancy and before delivery. Preeclampsia will be diagnosed if the patient has proteins excreted in urine (24-hour urine protein \>300 mg or urinary protein to creatinine ratio ≥ 0.3 or dipstick 2+) and persistent high blood pressure ≥ 140/90 mmHg for minimum of 4 hours or ≥160/110 mmHg),

Time frame
From enrollment at 11-14 weeks of pregnancy until delivery, up to 36 weeks of gestation

Secondary outcomes

1

Stillbirth

Proportion of pregnancies resulting in stillbirth. Stillbirth will be defined as delivery of baby with no signs of life.

Time frame
From enrollment at 11-14 weeks of pregnancy until delivery, up to 36 weeks of gestation

Other outcomes

1

Neonatal Birth Weight

Birth weight of the newborn measured in grams using a digital weighing scale within 3 hours of birth.

Time frame
From enrollment at 11-14 weeks of pregnancy until delivery, up to 36 weeks of gestation

Sponsors and contacts

Click on the lead sponsor to view all of their trials.